Medigene to present progress on KRAS library and UniTope & TraCR technology at ESMO 2024 Page 1

Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-directed therapies for the treatment of cancer, presented updates to its T cell receptor (TCR) library targeting the Kirsten rat sarcoma viral oncogene homolog (KRAS) and also highlighted the advancement of its UniTope and TraCR technology, which serves as a universal system for tagging and tracking recombinant TCRs (rTCRs) across multiple modalities, including T cell receptor-engineered T cell (TCR-T) therapies, at the ESMO Congress 2024, taking place from 13 to 17 September 2024 in Barcelona.

The presented posters “Developing a multidimensional KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations” And “UniTope & TraCR – Universal tagging and tracking system for TCR-T cells, directly integrated into the TCR constant region“will be available on Medigene’s website after the conference: https://medigene.com/science/abstracts/

“We are excited about our growing library of mKRAS-specific rTCRs targeting different mutations and HLA allotypes to broaden treatment options and improve outcomes for patients with difficult-to-treat solid tumors,” said Dolores Schendel, CSO at Medigene AG. “Our lead KRAS G12D candidate, enhanced by the costimulatory switch protein (CSP) PD1-41BB, has demonstrated promising T cell functionality. By overcoming the challenges of the tumor microenvironment that have hampered the effectiveness of TCR-T therapies, we are confident that this program can deliver best-in-class efficacy and safety. We are expanding our TCR library and also incorporating novel proprietary technologies into our End-to-End (E2E) platform, including UniTope & TraCR, a universal detection system for any rTCR across modalities such as TCR-T therapies, TCR-guided T cell engager therapies and TCR-NK cell therapies. Direct integration of the UniTope tag ensures 100% co-expression of a unique identifier within an rTCR sequence and offers a significant advance over current methods for detecting rTCRs in TCR-guided therapies. UniTope and TraCR will help us streamline quality control and provide accurate data to determine the right drug dosage for TCR-T therapies.”

Diskutieren Sie über die entaltenen Werte